- Respiratory syncytial virus (RSV) activity is increasing in California and across the US.
- An early wave of RSV activity and circulation of other respiratory viruses has led to increased hospitalizations among children and has contributed to stresses in the pediatric healthcare delivery system in California and across the US.
- Healthcare providers should promptly administer prophylactic palivizumab to infants and young children at high risk for RSV per American Academy of Pediatrics (AAP) guidance.
- RSV can cause serious disease in adults, especially in the elderly and in young children.
- Influenza activity in California has also started, and COVID-19 activity is increasing and both are expected to increase in the coming months, further stretching California hospital resources for both adults and children.
- All healthcare facilities, including facilities without existing pediatric services, should consider expanding capacity to evaluate and treat pediatric patients to manage the increase in patient volume. Healthcare providers should review and implement pediatric surge measures where appropriate, such as expanding outpatient clinic hours, inpatient care, and/or consultative services.
As RSV and other respiratory virus activity continues to evolve and new evidence emerges, California Department of Public Health (CDPH) will collaborate with local health departments to assess and provide additional updates as they become available. CDPH provides brief guidance below regarding vaccination, testing, treatment, and other preventive measures for respiratory viruses.
Vaccination & Chemoprophylaxis Prevention
- Healthcare providers are encouraged to test outpatients (children and adults) for influenza, SARS-CoV-2, and RSV (via multiplex assays if available) when feasible as testing may affect decisions regarding clinical management, treatment in high risk individuals, and infection control. Healthcare providers caring for children and adults with respiratory illnesses in inpatient and congregate settings should test for respiratory viruses, including influenza, SARS-CoV-2, and RSV.
- Treatment For high-risk patients with suspected influenza:
- Start influenza antiviral treatment immediately. Decisions about starting influenza antiviral treatment should not wait for laboratory confirmation of influenza. If the patient tests negative for influenza, influenza antiviral treatment can be discontinued.
- High-risk patients co-infected with influenza and SARS-CoV-2 should receive treatment for both viruses. There are no clinically significant drug-drug interactions between the antiviral agents or immunomodulators that are used to prevent or treat COVID-19 and those antiviral agents used to treat influenza.
- Prevention is a key element and is strongly encouraged to help stop the spread of respiratory viruses. Counsel patients about everyday actions that can stop the spread of respiratory viruses, as appropriate:
- Wear a mask in indoor public or crowded spaces. Wearing a mask can protect babies and young children who do not yet have immunity and are too young to wear a mask themselves.
- Wash hands frequently and thoroughly with soap and warm water or use an alcohol-based hand sanitizer.
- Cough or sneeze into your elbow, arm, or disposable tissue. If disposable tissue is used, use hand sanitizer or wash hands afterwards.
- Avoid touching your eyes, nose, and mouth.
- Stay away from people who are sick.
- Stay home when sick and encourage parents and caregivers to keep young children with acute respiratory illnesses out of childcare, even if they have a negative test for SARS-CoV-2. .
- Individuals may return to work/school/childcare after symptoms have resolved including at least 24 hours have passed since resolution of fever without the use of fever-reducing medications, such as Tylenol® or Motrin®. Patients who test positive for SARS- CoV-2 should follow CDPH isolation guidance.
Influenza Resources for Health Care Providers
Influenza and COVID-19 Resources for the Public